Novavax Stock Plummets as FDA Pauses Clinical Trial on Safety Concerns
In this article:
The regulator placed a clinical hold on its Covid-19-influenza combination vaccine after one person reported nerve damage.
Advertisement
Some parts of this page are not supported on your current browser version. Please upgrade to a recent browser version.
The regulator placed a clinical hold on its Covid-19-influenza combination vaccine after one person reported nerve damage.